|Michael R. Feldschuh, Director of the Company|
|Michael Feldschuh earned his bachelors degree in Pre-Med studies at Columbia College, Columbia University in 1991. Prior to joining Daxor’s executive team in December of 2014 he served as a member of the board of directors for one and a half years prior. Michael headed his own hedge fund, Aristarc Capital, from 2009 to 2013 specializing in quantitative strategies. Prior to founding his own fund, Michael was a Managing Director at Morgan Stanley from 2005 to 2009 and also served as a Managing Director and Portfolio Manager at Millennium Partners in New York from 1997-2005. Michael was a proprietary trader for Morgan Stanley & Co. from 1994-1997. Michael began his career at D.E. Shaw & Co. in New York, where he worked with Jeffery Bezos prior to Bezos’s founding of Amazon.|
|James A. Lombard, Director of the Company|
|James A. Lombard holds an undergraduate degree in Business Administration (BBA) from Iona College and a Master’s Degree (MBA) in Marketing, Banking, and Finance from New York University Graduate School of Business Administration. Mr. Lombard recently retired as Director, Administrative Services Division, City Council of New York and actively participates in civic and community affairs. Prior to joining the City Council, he worked in the field of banking, holding various administrative positions with Citicorp and other major Banking institutions.|
|Martin S. Wolpoff, Director of the Company|
|Martin S. Wolpoff holds B.A., M.A. and M.S. degrees from the City University of New York. He has been active in community affairs since the 1970’s. He has served on his local community Board (as a member for over two decades and its chair for three years), community School Board (member for nine years, president for three), Community Development Corporation (member for almost 10 years), and a member of the community advisory board for a New York City hospital. Mr. Wolpoff is retired from the New York City public school system, having served since 1965 as an educator, supervisor, and administrator. He is currently an educational consultant.|
|Edward S. Feuer, Director of the Company|
|Edward is a CPA and a Managing Partner of Feuer & Orlando LLP.
Edward is a member of the AICPA and The New York State Society of Certified Public Accountants where he has served on the State and Local Tax Committee and the Continuity of Practice Committee.
Edward graduated from George Washington University and Scarsdale High School. Prior to founding this firm Edward worked at the NYS Department of Taxation and Finance, Westvaco Corp., as well as two metropolitan CPA firms.His areas of specialty are professional service companies, broker dealers, mutual funds, high net worth individuals, wealth management, financial planning, business management and advisory. He reviews all financial statements issued by the firm. Edward is proud of the teamwork of the firm and its focus on the success of their clients.
Having more than 35 years of experience, Edward is seen by his clients as their trusted advisor. He is a strong proponent of the importance of client relationships. Loyal and appreciative clients are the hallmark of the firm’s growth.
|Bernhard Saxe, Director of the Company|
|Bernhard Saxe is a retired partner of Foley & Lardner, LLP, a general intellectual property practice, and former Vice President of Patent Affairs and Corporate Secretary of Immunomedics, Inc. He is a registered patent attorney and a member of American Intellectual Property Law Association, American Bar Association and American Chemical Society. He received his J.D. from George Washington University; NIH Postdoctoral Fellowship in Strasbourg, France; PhD from Columbia University; and his B.A. from Johns Hopkins University in chemistry. Mr. Saxe is listed among the top 10 patent prosecuting attorneys in Patent Hall of Fame: A Teacherâ€™s Tale, has authored multiple articles pertaining to patent law and participated in various seminars and lectures.|
|Jonathan Feldschuh, Chief Scientific Officer|
|Jonathan Feldschuh has been involved with developing Daxor’s technology for many years. He is a co-inventor on multiple Daxor patents, including the original patent covering the blood volume analyzer (BVA-100). Jonathan studied Physics at Harvard University, receiving an A.B. degree summa cum laude in 1986. Prior to taking on the role of CSO at Daxor, Jonathan worked extensively in technology and quantitative finance. He was the Chief Quantitative Office at Aristarc Capital, overseeing the research, development, and execution of quantitative trading strategies. Prior to Aristarc he worked in quantitative roles at financial firms such as Morgan Stanley, Millennium Partners, and American Express.|